| 000 | 01871 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517035642.0 | ||
| 264 | 0 | _c20160421 | |
| 008 | 201604s 0 0 eng d | ||
| 022 | _a1748-6963 | ||
| 024 | 7 |
_a10.2217/nnm.15.50 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSu, Xiao | |
| 245 | 0 | 0 |
_aCo-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance. _h[electronic resource] |
| 260 |
_bNanomedicine (London, England) _c2015 |
||
| 300 |
_a2033-50 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aATP Binding Cassette Transporter, Subfamily B, Member 1 _xgenetics |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCeramides _xadministration & dosage |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aGlucosyltransferases _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLiposomes |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xadministration & dosage |
| 650 | 0 | 4 |
_aUp-Regulation _xdrug effects |
| 700 | 1 | _aSong, Hao | |
| 700 | 1 | _aNiu, Fangfang | |
| 700 | 1 | _aYang, Kaixuan | |
| 700 | 1 | _aKou, Geng | |
| 700 | 1 | _aWang, Xiaohang | |
| 700 | 1 | _aChen, Huaiwen | |
| 700 | 1 | _aLi, Wei | |
| 700 | 1 | _aGuo, Shangjing | |
| 700 | 1 | _aLi, Jun | |
| 700 | 1 | _aLi, Bohua | |
| 700 | 1 | _aFeng, Si-Shen | |
| 700 | 1 | _aJiang, Jianxin | |
| 700 | 1 | _aYin, Chuan | |
| 700 | 1 | _aGao, Jie | |
| 773 | 0 |
_tNanomedicine (London, England) _gvol. 10 _gno. 13 _gp. 2033-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/nnm.15.50 _zAvailable from publisher's website |
| 999 |
_c24991704 _d24991704 |
||